3 ms·
Paxlovid for vaccinated non-risk groups most likely is useless and the suggestion to distribute it like candy is simply irresponsible. Initial studies were don
by NoPie 4y ago
Paxlovid for vaccinated non-risk groups most likely is useless and the suggestion to distribute it like candy is simply irresponsible.
Initial studies were done with non-vaccinated risk groups and it showed a good efficiency. Since then most people have already been vaccinated and the benefit for them is probably lesser. The post-marketing studies showed that it doesn't help people under 50 y.o.
The other issue is with covid rebound when using Paxlovid. In the studies rebound was something like 2-3%, in practice it happens much more often which can also indicate that the study population that was benefitting from Paxlovid is different from the one that is taking it now.
- guelo 4y agoIt's only irresponsible because of the limited supply. Safety-wise it's fine to take, even if it's basically a placebo for the under-50s. Also the published stats are about hospitalization, we don't seem to have data on other possible benefits such as shortened sickness or reduced long-covid risk. Though I read somewhere that the long-covid research is being done.
- NoPie 4y agoIf you are a health young male then it is probably safe but it is not safe for some people (people with other medications, liver problems etc.). For example, someone taking immunosuppressants due to organ transplant may have treatment failure which can lead to transplant rejection. This is the reason why it is the prescription only medicine and is prescribed only after assessing the patient. Those other benefits are minor compared to potential harm.